Syndax Pharmaceuticals
Clinical trials sponsored by Syndax Pharmaceuticals, explained in plain language.
-
Last-Resort drug access for leukemia patients opens
Disease control NO_LONGER_AVAILABLEThis program provides an experimental drug, SNDX-5613, to patients with relapsed or refractory acute leukemias who have no approved treatments left and cannot join other studies. It aims to offer a potential option in a controlled setting for those aged 6 months and older. The dr…
Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 09:44 UTC
-
New drug axatilimab tested to slow lung scarring in IPF patients
Disease control OngoingThis study tests a drug called axatilimab in 145 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The goal is to see if axatilimab can slow the decline in lung function over 26 weeks compared to a placebo. Participants rece…
Phase: PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New hope for transplant patients with stubborn GVHD
Disease control OngoingThis study tests a drug called axatilimab in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where the donor cells attack the patient's body. Participants must have tried at least two other treatments without success. The goal is…
Phase: PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:50 UTC